In a prospective study of 52 consecutive women who required acceleration of labour intravenous prostaglandin E2 (PGE,) was used as the oxytocic agent. These mothers were matched for age, parity, height, gestational age, initial cervical dilatation, and station and position of the fetal head with 52 women whose labours were accelerated with oxytocin; both drugs were equally effective. Acceleration to delivery intervals, second-stage durations, the number of assisted deliveries, and Apgar scores were similar regardless of the oxytocic used.
Introduction
The active management of labour has become standard obstetric practice. The benefits offered to the mother and fetus have been shown in several studies.1 The use of intravenous oxytocin to accelerate labour when progress is unsatisfactory is an important aspect of this policy. The value of intravenous prostaglandin E, (PGE2) for accelerating slow labour has not been clearly defined, however; there have been two contradictory reports on this subject. 3 Our aim was to compare the relative efficacy of intravenous PGE2 and oxytocin (Syntocinon) for accelerating labour and to establish whether there are any special circumstances when the use of intravenous PGE2 would be preferable.
Patients and methods
In a prospective study 52 consecutive patients who required acceleration of labour were given intravenous PGE2. These patients were then compared with a matched sample of patients whose labours were accelerated with intravenous oxytocin. The latter were selected from a series of patients whose labour required acceleration immediately after the completion of the intravenous PGE2 study. [2] [3] [4] [5] Htg/min; for oxytocin the infusion rate was 2-64 mU/min. Conventional parenteral analgesia was administered as required, and no patient was given epidural analgesia.
Student's t test was applied to assess the significance of differences between the two groups.
Results
In both primigravidae and multiparae the mean acceleration to delivery intervals when labour was accelerated with intravenous PGE2 were not significantly different from those after the use of intravenous oxytocin (table II) ; the second stage durations were also similar (P>0-1 in both cases). When the cervical dilatation at acceleration was 5 cm or less the mean acceleration to delivery intervals were similar (P > 0-05). This also applied when the initial cervical dilatation was greater than 5 cm (table III) . The incidence of side effects, fetal heart irregularities, low Apgar scores, neonatal jaundice, and assisted deliveries was similar. Only two patients who received PGE2 developed phlebitis. No patient in either group developed uterine hypertonus.
Discussion
Intravenous PGE2 appears to be as effective as oxytocin in accelerating labour. Clegg et a13 reported a significantly shorter acceleration to delivery interval when intravenous PGE2 was used to accelerate labour, but we found that both the acceleration to delivery interval and second-stage duration were similar, irrespective of the oxytocic agent used. Cervical dilatation before acceleration of labour was irrelevant so far as the choice of oxytocic was concerned; both drugs were equally effective at different stages of cervical dilatation.
In contrast to the findings of an earlier study,4 oxytocin showed no advantage over PGE2 in expediting delivery in primigravidae. The instrumental delivery rate was similar, regardless of the drug used. Likewise, in multiparae both drugs proved to be equally effective.
Intravenous PGE, carefully administered on a dose-response titration basis seems to cause few maternal side effects. Moreover, its use for accelerating labour does not cause an increased risk to the fetus compared with oxytocin. Nevertheless, PGE2 offers no special advantages over oxytocin when used to accelerate labour. Oxytocin is cheaper, well tried, and has proved to be as free of side effects. Consequently, we recommend its continued use for stimulating inert labour. 
Bran tablets and diverticular disease I TAYLOR, H L DUTHIE
British Medical_Journal, 1976, 1, 988-990 Summary Three treatments for patients with symptomatic diverticular disease were compared in a crossover trial. Neither a high-roughage diet (HRD) nor Normacol plus an antispasmodic were as effective as bran tablets, which produced a significant increase in daily stool weight and a decrease in the intestinal transit time. An abnormal rapid electrical rhythm in colonic smooth muscle was found initially in 80%' of the patients, but the incidence was reduced by each treatment after one month; it was present in only 40"' of patients after treatment with bran tablets. Only bran significantly reduced the high percentage motility to within normal limits.
Bran proved to be the most effective treatment, not only in improving the symptoms in patients with diverticular disease but also in returning to normal the abnormal pathophysiological changes. Bran tablets were both convenient and acceptable as well as effective.
Introduction
Many workers have associated a lack of cereal fibre in the diet with the development of diverticular disease. The initial experimental work was performed in 1949 by Carlson and Hoelzel,l who found that rats fed on a low-residue diet developed diverticula while those fed on a high-residue diet were unaffected. Since then much epidemiological evidence has supported this hypothesis. It has been estimated on the basis of barium enema and necropsy studies2 3 that up to 20%o of people over the age of 40, and 70°,, over the age of 70, in both the UK and USA have evidence of diverticular disease, whereas fewer than 12 cases have been observed in rural Africa in the last 20 years.46 The most important dietary difference in these societies seems to be a considerable reduction of fibre intake and an excess of refined carbohydrate in the Western diet.6
Clinical improvement in patients with diverticula fed highresidue diets is now well documented,' but controversy still exists on the most effective form of bulk replacement.8 9 We have compared both symptomatic and objective improvement in patients with diverticular disease using three standard regimens: a high-roughage diet with bran supplements (HRD), a bulk laxative (Normacol plus an antispasmodic), and regular large quantities of bran (in the form of bran tablets). Each bran tablet contained 2 g of bran and nine tablets were prescribed each day in divided doses. Patients taking the high-roughage diet were told which foods were high in fibre content and given a
